In Europe and North America, the influenza vaccination rate is about 20% to 40%. In China, this figure is only 2%. The pharmaceutical company Sanofi-Aventis smells opportunity.
China Business Daily reports that Sanofi-Aventi will invest €7 million to build a new vaccination prodction facility in Shenzhen. The article continues: “after the company’s the pharmaceutical factory in Shenzhen officially put into operation in 2012, the company could sell 2.5 million seasonal influenza vaccine in China.”